Diagnostika i lechenie oteka legkikh


Cite item

Full Text

Abstract

В 60–70% случаев причиной развития отека легких является ишемическая болезнь сердца (ИБС), у 26% пациентов причиной развития отека легких является хроническая сердечная недостаточность (ХСН), у 9% – острые нарушения ритма, у 3% – патология клапанов [5–8]. В пожилом возрасте среди причин развития отека легких преобладает ИБС, тогда как в молодом возрасте среди этиологических факторов превалируют дилатационная кардиомиопатия, пороки сердца и миокардиты. Важно отметить, что ОСН может развиться и без предшествующей патологии, т.е. начало заболевания протекает в виде отека легких. В исследовании EHFS среди 11 327 пациентов, госпитализированных с ОСН, у 17% СН развилась в течение 3 мес, а в 40% случаев ОСН развивалась остро без предшествующего анамнеза [6]. Данные исследования EHFS II, проведенного в 133 центрах Европы в 2005 г., показали, что ОСН de novo регистрировалась у 37% пациентов, причем 42% этих пациентов имели острый коронарный синдром (ОКС)

About the authors

S. N Tereshchenko

ГОУ ВПО МГМСУ

I. V Kositsyna

ГОУ ВПО МГМСУ

N. A Gnidkina

ГОУ ВПО МГМСУ

References

  1. Swedberg K, Nieminen M.S Cleland J at al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary. The task force for the diagnosis and treatment of chronic heart failure of the European Society of Cardiology. Eur Heart J 2005; 26: 1115–40.
  2. Jessup M, Brozena S. Heart Failure NEJM 2003; 348 (20): 2007–18.
  3. Alla F, Zannad F, Filippatos G Epidemiology of acute heart failure syndromes at Heart Fail Rev. 2007 12(2) 91–5
  4. Konstam M.A. Progress in heart failure management? Lessons from the real world. Circulation 2000; 102: 1076–8.
  5. Khand A, Gemmel I, Clark A.L, Cleland J.G. Is the prognosis of heart failure improving? J Am Coll Cardiol 2000; 36: 2284–6.
  6. Cleland J.G, Swedberg K, Follath F et al. The EuroHeart Failure survey programme - a survey on the quality of care among patients with heart failure in Europe. Part 1: Patient characteristics and diagnosis. Eur Heart J 2003; 24: 442–63.
  7. Fox K.F, Cowie M.R, Wood D.A et al. Coronary artery disease as the cause of incident heart failure in the population. Eur Heart J 2001; 22: 228–36.
  8. Al-Khadra A.S, Salem D.N, Rand W.M et al. Warfarin anticoagulation and survival: a cohort analysis from the studies of left ventricular dysfunction. J Am Coll Cardiol 1998; 31: 749–53.
  9. Mosesso V.N, Dunford J, Blackwel T, Griswell J.K. Prehospital therapy for acute congestive heart failure: state of the art. Prehospital Emergency Care J 2003; 7: 13–23.
  10. Nieminen M.S, Brutsaert D, Dickstein K at al. EuroHeart Failure Survey II): a survey on hospitalized acute heart failure patients: description of population European Heart J 2006; 27 (22): 2725–36.
  11. Cotter G, Kaluski E, Moshkovitz Y et al. Pulmonary edema: new insight on pathogenesis and treatment. Curr Opin Cardiol 2001; 16: 159–63.
  12. Mitchell J.E, Palta S. New diagnostic modalities in the diagnosis of heart failure.J Natl Med Assoc 2004; 6 (11): 1424–30.
  13. Berger R, Huelsman M, Strecker K et al. B - type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation 2002; 105: 2392–7.
  14. Torbjоrn Omlandt Heart failure in the emergency department*: Is B - type natriuretic peptide a better prognostic indicator than clinical assessment? J Am Col Cardiol 2004; 44 (6): 1334–6.
  15. Muders F, Kromer E.P, Griese D.P et al. Evaluation of plasma natriuretic peptides as markers for left ventricular dysfunction. Am Heart J 1997; 134: 442–9.
  16. Maeda K, Takayoshi T, Wada A et al. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end - diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J 1998; 135: 825–32.
  17. Aberle D.R, Wiener-Kronish J.P, Webb W.R, Matthay M.A. Hydrostatic versus increased permeability pulmonary edema: diagnosis based on radiographic criteria in critically ill patients. Radiology 1988; 168: 73–9.
  18. Duane P.G, Colice G.L. Impact of noninvasive studies to distinguish volume overload from ARDS in acutely ill patients with pulmonary edema: analysis of the medical literature from 1966 to 1998. Chest 2000; 118: 1709–17.
  19. Ware L.B, Matthay M. Acute Pulmonary Edema NEJM 2005; 353 (26): 2788–96.
  20. Swan H.J, Ganz W, Forrester J et al. Catheterizationof the heart in man with use of a flow - directed balloon - tipped catheter. N Engl J Med 1970; 283: 447–51.
  21. Masip J, Betbese A.J, Paez J et al. Non - invasive pressure support ventilation versus conventional oxygen therapy in acute cardiogenic pulmonary oedema: a randomised trial. Lancet 2000; 356: 2126–32.
  22. Sharon A, Shpirer I, Kaluski E et al. High - dose intravenous isosorbide - dinitrate is safer and better than Bi - PAP ventilation combined with conventional treatment for severe pulmonary edema. J Am Coll Cardiol 2000; 36: 832–7.
  23. Brater D.C. Resistance to loop diuretics. Why it happens and what to do about it. Drugs 1985; 30: 427–43.
  24. Kramer W.G, Smith W.B, Ferguson J et al. Pharmacodynamics of torsemide administered as an intravenous injection and as a continuous infusion to patients with congestive heart failure. J Clin Pharmacol 1996; 36: 265–70.
  25. Channer K.S, Mc Lean K.A, Lawson-Matthew P et al. Combination diuretic treatment in severe heart failure: a randomised controlled trial. Br Heart J 1994; 71: 146–50.
  26. Cotter G, Metzkor E, Kaluski E et al. Randomised trial of high - dose isosorbide dinitrate plus low - dose furosemide versus high - dose furosemide plus low - dose isosorbide dinitrate in severe pulmonary oedema. Lancet 1998; 351: 389–93.
  27. Cotter G, Weissgarten J, Metzkor E et al. Increased toxicity of highdose furosemide versus low - dose dopamine in the treatment of refractory congestive heart failure. Clin Pharmacol Ther 1997; 62: 187–93.
  28. Katz A.M. Potential deleterious effects of inotropic agents in the therapy of chronic heart failure. Circulation 1986; 73: III184–III90.
  29. Kivikko M, Lehtonen L, Colucci W.S. Sustained hemodynamic effects of intravenous levosimendan. Circulation 2003; 107: 81–6.
  30. Innes C.A, Wagstaff A.J. Levosimendan: A review of its use in the management of acute decompensated heart failure. Drugs 2003; 63: 2651–71.
  31. Follath F, Cleland J.G, Just H et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low - output heart failure (the LIDO study): a randomised double - blind trial. Lancet 2002; 360: 196–202.
  32. Slawsky M.T, Colucci W.S, Gottlieb S.S et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators. Circulation 2000; 102: 2222–7.

Copyright (c) 2008 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies